博瑞生物医药（苏州）股份有限公司 舆情管理制度 第一章 总则 第一条 为提高博瑞生物医药（苏州）股份有限公司（以下简称"公司"）应 对各类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对 公司股价、商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益， 根据相关法律法规、规范性文件和《博瑞生物医药（苏州）股份有限公司章程》 （以下简称"公司章程"）等规定，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）社会上存在的已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息； （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第六条 公司董事会办公室为舆情管理工作的日常职能部门，由董事会秘书 直接领导。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情（尤其是媒体质疑危机时）实行统一领导、统一 组织、快速反应、协同应对。 第四条 公司舆情管理工作由公司董事会统一领导和管理，董事长作为第一 责任人，负责领导各类舆情处理工作。必要时 ...

博瑞生物医药（苏州）股份有限公司 2024 年度独立董事述职报告 作为博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"） 的独立董事，2024 年度本人严格按照《公司法》《证券法》《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 《公司章程》等相关规定，认真履行职责，及时了解公司运营情况，积极出席公 司股东大会、董事会及专门委员会、独立董事专门会议相关会议，并对审议的相 关事项发表了独立、客观的意见。本人从维护公司整体利益出发，充分发挥专业 特长，为公司的经营发展提出合理化建议，促进公司健康持续发展，切实维护了 公司和股东特别是中小股东的合法权益。现将 2024 年度任期内履职情况汇报如 下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 吴英华，1970 年 6 月出生，中国国籍，无境外永久居留权，本科学历，中国 注册会计师，中国注册会计师协会资深会员。历任江苏吴江农村商业银行股份有 限公司独立董事、江苏永鼎股份有限公司独立董事、苏州亚德林股份有限公司独 立董事。现任吴江华正会计师事务所副主任会计师、苏州欧福蛋业股份有限公司 ...

博瑞生物医药（苏州）股份有限公司 2024 年度独立董事述职报告 作为博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"） 的独立董事，2024 年度本人严格按照《公司法》《证券法》《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 《公司章程》等相关规定，认真履行职责，及时了解公司运营情况，积极出席公 司股东大会、董事会及专门委员会、独立董事专门会议相关会议，并对审议的相 关事项发表了独立、客观的意见。本人从维护公司整体利益出发，充分发挥专业 特长，为公司的经营发展提出合理化建议，促进公司健康持续发展，切实维护了 公司和股东特别是中小股东的合法权益。现将 2024 年度任期内履职情况汇报如 下： 一、独立董事的基本情况 （一）本人工作履历、专业背景以及兼职情况 RUYI HE（何如意），1961 年 3 月出生，美国国籍，医学博士。曾任职于中 国医科大学附属第一医院、美国国家卫生研究院、美国 Howard 大学医学院附属 医院、美国 FDA 新药审评办公室消化及罕见病药物审评部、CFDA 药品评审中 心等；现任国投创新医疗健康首席科学家，荣昌生物制 ...

博瑞生物医药（苏州）股份有限公司 2024 年度独立董事述职报告 作为博瑞生物医药（苏州）股份有限公司（以下简称"博瑞医药"或"公司"） 的独立董事，2024 年度本人严格按照《公司法》《证券法》《上市公司独立董事 管理办法》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 《公司章程》等相关规定，认真履行职责，及时了解公司运营情况，积极出席公 司董事会相关会议，并对审议的相关事项发表了独立、客观的意见。本人从维护 公司整体利益出发，充分发挥专业特长，为公司的经营发展提出合理化建议，促 进公司健康持续发展，切实维护了公司和股东特别是中小股东的合法权益。现将 2024 年度任期内履职情况汇报如下： 程增江，1966 年 6 月出生，中国国籍，无境外永久居留权，博士研究生学 历。曾任山东省济南军区药检所主管药师，北京市解放军 301 医院助理研究员， 北京正力健医药科技公司/北京悦康集团思普润安医药科技有限公司技术总监/总 经理，四环医药控股集团研发总监等职。现任同写意（北京）科技发展有限公司 董事长，科贝源（北京）生物医药科技有限公司董事长。兼任中国食品药品企业 质量安全促进会副会长，中国医药 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,282,551,614.50, representing an increase of 8.74% compared to ¥1,179,517,532.47 in 2023[20]. - The net profit attributable to shareholders decreased by 6.57% to ¥189,166,937.36 in 2024 from ¥202,466,024.77 in 2023[20]. - The basic earnings per share for 2024 was ¥0.45, down 6.25% from ¥0.48 in 2023[21]. - The company's cash flow from operating activities increased by 26.08% to ¥245,559,317.10 in 2024 compared to ¥194,765,466.05 in 2023[20]. - The total assets of the company at the end of 2024 were ¥5,164,346,157.48, reflecting a 2.63% increase from ¥5,031,831,375.92 at the end of 2023[20]. - The company reported a net profit of ¥64,069,918.71 in Q1 2024, with a total operating revenue of ¥340,133,145.78 for the same quarter[27]. - The company reported a total revenue of 74,976 million RMB, with a net profit of 20,262 million RMB, reflecting a significant increase compared to the previous period[99]. Research and Development - Research and development expenses accounted for 24.31% of operating revenue in 2024, an increase of 3.23 percentage points from 21.08% in 2023[21]. - The company reported a total R&D investment of ¥311,789,789.39, an increase of 25.42% compared to the previous year[95]. - The proportion of R&D investment to operating income rose to 24.31%, up by 3.23 percentage points year-on-year[95]. - The company is focusing on developing innovative drugs in the metabolic disease field, with a significant increase in investment for innovative drugs and inhalation formulations, up 97.30% and 52.27% respectively[35]. - The company has submitted 41 domestic patent applications and obtained 28 domestic patent grants during the reporting period, with a total of 506 patent applications filed to date[40]. - The company is developing multiple innovative drug products, including BGM0504, a dual agonist for GLP-1 and GIP, currently in Phase III clinical trials[98]. - The cumulative investment in the BGM0504 injection project reached ¥13,154.44 million, with a current period investment of ¥7,139.87 million[98]. Market Strategy and Positioning - The company plans to enhance its market position through mergers and acquisitions as part of its strategy to increase market concentration in the pharmaceutical industry[32]. - The company has established a comprehensive marketing strategy to enhance hospital coverage and market share for its products, including winning bids in national drug procurement[48]. - The company is actively tracking global cutting-edge technologies and has made equity investments in innovative biotech companies to support future drug pipeline development[45]. - The company aims to expand its product pipeline by focusing on GLP-1 class drugs and exploring multi-target therapies to address unmet clinical needs[193]. - The company is committed to continuous innovation and aims to develop high-end generics and original new drugs to meet clinical demands and improve patient accessibility[200]. Risks and Challenges - The company has detailed various risks faced in its operations, which are elaborated in the management discussion and analysis section[3]. - The company faces risks related to the lengthy and costly process of generic drug development, which may impact its future performance[108]. - The company is exposed to risks from product substitution if it fails to maintain technological innovation and competitive advantages[114]. - The company must navigate evolving pharmaceutical industry policies, which could impact its operational and competitive landscape[123]. - The company faces potential risks from safety production incidents that could disrupt normal operations[116]. Corporate Governance and Compliance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties[6]. - The company has received a standard unqualified audit report from the accounting firm Tianye[3]. - The company has not disclosed any special arrangements for corporate governance[5]. - The company has not violated any decision-making procedures regarding external guarantees[6]. - The company has confirmed that all directors can guarantee the authenticity, accuracy, and completeness of the annual report[7]. Investment and Financial Management - The company raised CNY 465 million through convertible bonds for the construction of a new production base, focusing on high-tech barrier products[41]. - The company maintained a balanced investment strategy, resulting in a net cash outflow from investment activities of -440,141,524.14 CNY[129]. - The company’s investment in foreign exchange derivatives amounted to CNY 181,138,800.00, with a total loss of CNY 2,543,663.64 reported during the period[182]. - The company’s financial department will continuously monitor the market prices of foreign exchange derivatives and report any anomalies to management[183]. Product Development and Innovation - The company has established multiple core drug research and development technology platforms, including fermentation semi-synthesis and multi-chiral drug technology platforms, enhancing its competitive edge in the pharmaceutical industry[58]. - The company is prioritizing the development of antibody-drug conjugates (ADCs), which have gained FDA approval, indicating a significant focus on targeted cancer therapies[88]. - The company has established a fermentation semi-synthesis platform, successfully developing high-value products such as Caspofungin and Micafungin, with several formulations receiving European market approval[78]. - The company is focusing on the development of generic drugs that are relatively scarce in the market and have high technical difficulty[163]. Global Market Trends - The global pharmaceutical market reached $1,495 billion in 2022 and is expected to grow to $2,090 billion by 2030, with significant growth driven by increasing healthcare spending and drug approvals[64]. - The Chinese pharmaceutical market is projected to reach ¥2,624.5 billion by 2030, with a current per capita expenditure of $163.60, significantly lower than the U.S. at $1,745.30[64]. - The global GLP-1 receptor peptide drug market reached $17 billion in 2021 and is expected to grow to $90.8 billion by 2030, driving rapid growth in the overall peptide drug market, which is projected to reach $210.8 billion by 2030[194].

一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.4500 | 0.4800 | -6.25 | 0.5800 | | 每股净资产（元） | 0 | 5.43 | -100 | 5.01 | | 每股公积金(元) | 2.33 | 2.5 | -6.8 | 2.39 | | 每股未分配利润(元) | 2.27 | 1.97 | 15.23 | 1.62 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 12.83 | 11.8 | 8.73 | 10.17 | | 净利润(亿元) | 1.89 | 2.02 | -6.44 | 2.4 | | 净资产收益率(%) | 7.77 | 8.84 | -12.1 | 12.68 | 数据四舍五入，查看更多财务数据>> | 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例 ...

Group 1 - The recombinant protein concept sector rose by 2.32%, ranking fifth among concept sectors, with 40 stocks increasing in value [1] - Notable gainers in the sector included Xilong Science, which hit the daily limit, and other companies like Maiwei Biotech, Hotgen Biotech, and Zexin Pharmaceutical, which rose by 11.05%, 8.16%, and 7.91% respectively [1] - The sector experienced a net inflow of 354 million yuan from main funds, with 23 stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top stocks by net inflow included Xilong Science with 282 million yuan, followed by Huabei Pharmaceutical, Borui Pharmaceutical, and Maiwei Biotech with net inflows of 29.71 million yuan, 27.06 million yuan, and 14.97 million yuan respectively [2][3] - Xilong Science led the sector with a net inflow rate of 30.58%, followed by Innotec and Kexing Pharmaceutical with rates of 13.12% and 11.83% respectively [3] - The overall performance of the recombinant protein sector reflects strong investor interest and capital flow, indicating potential growth opportunities within this industry [2][3]

证券代码：688166 证券简称：博瑞医药 公告编号：2025-004 博瑞生物医药（苏州）股份有限公司 自愿披露关于硫酸艾沙康唑原料药获得上市申请批 准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，博瑞生物医药（苏州）股份有限公司（以下简称"公司"）全资子公司 博瑞制药（苏州）有限公司收到国家药品监督管理局签发的"硫酸艾沙康唑"《化 学原料药上市申请批准通知书》。 现就相关信息公告如下： 一、产品基本信息 生产地址：泰兴经济开发区通园路 10 号 二、药品的其他相关情况 硫酸艾沙康唑用于治疗成人患者下列感染：侵袭性曲霉病、侵袭性毛霉病。 硫酸艾沙康唑对应的制剂主要为注射用硫酸艾沙康唑，据统计，注射用硫酸 艾沙康唑 2022 年国内销售额为 0.02 亿元、2023 年国内销售额为 1.36 亿元、2024 年国内销售额为 1.67 亿元（数据来源于医药魔方 Pharmcube IPM©数据库）。 三、对公司的影响及相关风险提示 登记号：Y20230000572 化学原料药名称：硫酸艾沙康唑 包装规格 ...

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, focusing on innovation, overseas expansion, thematic investments, and dividend strategies as the main investment themes [2][17]. Core Insights - The pharmaceutical sector experienced a short-term pullback but remains optimistic about the innovation-driven growth trajectory. Key areas of focus include innovative drugs, international market expansion, and supportive policies for innovation [2][17]. - The report highlights the importance of innovative drugs as a new productive force, with significant policy support expected to accelerate their development [17]. - The report emphasizes the potential of companies with strong clinical pipelines and innovative capabilities, particularly in the context of recent supportive policies for innovative drugs [16][17]. Summary by Sections Current Industry Investment Strategy - The pharmaceutical index fell by 2.72% in the week, underperforming the CSI 300 index by 1.97 percentage points. Year-to-date, the sector has risen by 1.11%, outperforming the CSI 300 by 1.75 percentage points [15]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 26.53 times, with a premium of 75.91% relative to the entire A-share market [15]. Key Companies and Their Performance - **Hengrui Medicine**: Recent updates on lung cancer data show promising results, with an overall response rate (ORR) of 73% and median progression-free survival (mPFS) of 11.5 months, indicating strong commercial potential [16]. - **Innovative Drug Policies**: New policies are expected to encourage commercial insurance companies to invest in innovative drug companies and improve pricing standards [16][17]. Thematic Investment Lines - **Innovation and Overseas Expansion**: The report identifies innovative drugs as a key area, with a high success rate in recent insurance negotiations for innovative drugs [17]. - **Dividend Strategy**: With the 10-year government bond yield falling below 2%, dividend-paying assets with stable growth and cash flow are highlighted as defensive and offensive investment options [9][18]. Recommended Investment Combinations - The report lists several recommended stocks, including Hengrui Medicine, Enhua Pharmaceutical, and Yifan Pharmaceutical, among others, indicating a strong buy rating for these companies based on their growth potential and market performance [19][22].

Financial Performance - In 2024, the company achieved total operating revenue of RMB 128,255.16 million, a year-on-year increase of 8.74% driven by product sales growth[6] - The net profit attributable to the parent company was RMB 19,628.50 million, a decrease of 3.05% compared to the previous year, primarily due to increased R&D expenses related to products like BGM0504 injection[6] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 18,620.97 million, showing a slight decrease of 0.06% year-on-year[6] - Basic earnings per share for the period were RMB 0.46, down 4.17% from RMB 0.48 in the previous year[4] - The weighted average return on net assets decreased by 0.74 percentage points to 8.10%[4] Assets and Equity - The company's total assets at the end of 2024 were RMB 516,636.75 million, reflecting a growth of 2.67% from the beginning of the period[6] - The equity attributable to the parent company increased to RMB 240,136.31 million, up 1.38% from the start of the year[6] Research and Development - The company continues to adhere to a "R&D-driven" strategy, which has led to increased investment in product development[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final figures to be confirmed in the annual report[8] - Investors are advised to be aware of investment risks associated with the preliminary financial data[8]